Citations

Clear

117 citation(s) found for "Carson, C C".

Analysis of Complications Associated with Basivertebral Nerve Ablation for Vertebrogenic Low Back Pain: A Multicenter Retrospective Cohort Study of 1,145 Patients
Hoelzer, Bryan C. , Obray, Acelan, Naidu, Ramana, Cooper, Amanda , McCormick, Zachary L, Kanjanapanang, Napatpaphan , Moore, Greg, Her, Yeng F , Pittelkow, Thomas P. , Olatoye, Oludare, Freeman, Eric, Parker, Mikayla, Mitchell, Ellie A, Peterson, Lucas, Childs, Bryson, Eckstrom, Erik, Ekstrom, Petra V, Haugen, Lindsey A, Hamann, Ashley L, Carson, Grace G, Mayeri, Alyssa S, Peterson, Candance M, Fortin, Hayden E, Cooper, Amanda

Mayo Clinic

Pain Medicine | September 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/pm/pnag122 | PMID 42765343 Get It

Abstract Objective Low back pain (LBP) is a leading cause of pain and disability worldwide. Recent studies demonstrate a vertebrogenic model involving the basivertebral nerve (BVN) as a cause of chronic LBP. Vertebral endplates are highly innervated by the BVN, and literature shows type 1 and 2 Modic changes at vertebral endplates are a source of vertebrogenic low back pain (VBP). As a result, intraosseous radiofrequency ablation of the BVN is a minimally invasive outpatient procedure used to treat VBP. We conducted a retrospective review of 1,145 patients that have undergone BVN ablation to assess for safety and complication management. Methods Chart reviews were conducted to obtain demographic and pre-procedural information regarding patient gender, age at the time of BVN ablation, duration of LBP, and BMI. Post-procedure information derived from chart notes included vertebral levels ablated and post-BVN ablation complications, which were categorized as increased LBP > 7 days, increased radicular pain > 7 days, lower extremity weakness, infection, vertebral compression fracture, superficial bleeding, spinal or epidural hematoma, serious neurological injury, visit to the ER, and deep vein thrombosis/clot. Results 1,145 patient charts were reviewed showing an overall complication rate of 3.2% (37 complications). Increased radicular pain was the most common complication at 2.2% (25 complications) and resolved completely in all but one patient. The overall complication rate fell to 1.1% (13 complications) when the 24 cases of transient radicular pain were not counted as adverse events. Conclusions In this multicenter retrospective review, the overall rate of complications related to BVN ablation was low (3.2%). The most common complication was temporary radicular pain that resolved with conservative care. These findings suggest that BVN ablation is a safe treatment for VBP in real-world clinical settings.
Repurposing the PMFF Pedicle Before Final Division: Distal Necrosis Salvage With Long‐Term Success
Gates, Carson , Daher, Ghazal S. , Hamilton, Grant S., Hamilton, Grant S.

Mayo Clinic

The Laryngoscope | August 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/lary.70765 | PMID 42578308 Get It

Multi-center Phase 1 study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
Chauhan, Aman , Weiss, Heidi L. , Kunos, Charles , Jayswal, Rani , Konda, Bhavana , Soares, Heloisa P. , Li, Daneng , Hálfdánarson, Þorvarður R. , Mulcahy, Mary F. , Jacene, Heather A. , Khurana, Aman , Modak, Rakhi , Christner, Susan M., Das, Biswajit , Gore, Steven D. , Kohn, Elise C. , Anthony, Lowell , Yan, Donglin , Beumer, Jan Hendrik , Christner, Susan M , Wu, Peter I-Fan , Das, Biswasjit , Rubinstein, Larry V , Gore, Steven D , Ivy, S. Percy , Kohn, Elise C , Carson, William E , Anthony, Lowell B , Arnold, Susanne M , Halfdanarson, Thorvardur R , Mulcahy, Mary F , Soares, Heloisa P , Li, Daneng , Wu, Peter I-Fan , Rubinstein, Larry , Carson, William E. , Arnold, Susanne M.

Mayo Clinic

Clinical Cancer Research | July 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/1078-0432.ccr-26-0686 | PMID 42518206 Get It

Abstract Introduction: Next generation of Theranostics studies are looking at novel combinations with radiation sensitizers to enhance PRRT’s efficacy. Here, we present safety and efficacy data from a multi-center phase 1 study of a [¹⁷⁷Lu]lutetium-dotatate -triapine combination in patients with GEP-NETs. Methods: The study consisted of two phases (dose escalation and expansion) administering the recommended phase 2 doses (RP2D) for the two agents. All patients received 200 mCi of [¹⁷⁷Lu]lutetium-dotatate on day 1 of four 8-week cycles, in combination with oral triapine administered at assigned dose levels (100 mg, 150 mg or 200mg) from days 1 to 14 of each cycle. Results: A total of 31 (A: 15 ; B: 16 ) patients received treatment. Nine patients experienced dose-limiting toxicities; Grade 3 anemia (n=1), Grade 5 cardiac arrest (n=1), and Grade 4 neutropenia (n=7). Based on the overall safety and pharmacokinetics data, a [¹⁷⁷Lu]lutetium-dotatate (200 mCi) plus triapine (150 mg) dose was selected as the RP2D for the expansion phase. Grade ≥3 treatment related adverse events were observed in 77% patients: anemia (23%), nausea and vomiting (3% ), lymphopenia ( 58%), neutropenia ( 35%) and leukopenia ( 39%). The majority of cytopenias were transient and resolved within two weeks. Among the 28 evaluable patients, the objective response rate (ORR) was 21.4% and the median progression-free survival (mPFS) has not been reached (median follow-up period: 23.7 months). Conclusions: The combination of [¹⁷⁷Lu]lutetium-dotatate (200 mCi) and oral triapine (150 mg D1-14) was well tolerated and demonstrated preliminary activity in patients with well-differentiated GEP-NETs. (NCT04234568).
Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
A, Prera Vilaseca, Bilodeau, Philippe, Gakis, Georgios , Savransky, Andrea, Oliveira, Joao Mahler Ferreira, Nguyen, Linda, Hooshmand, Sam I., Satyanarayan, Sammita , Moseley, Carson E., Haley, Leah , Roy-Hewitson, Chantal, Marrodan, M, Casallas, Adriana, Manín, Analisa , Chen, H, Grzezulkowska, Aniela, Contentti, Edgar Carnero, Galleguillos, Lorna, Upchurch, Margaret, Jackson-Tarlton, Caitlin S. , Guo, Joanne Chu-Yueh, Fabian, Michelle, Caparó-Zamalloa, César, Paterno, R, Waubant, Emmanuelle, Boschetti, Laura Ordoñez, Correale, Jorge, Villa, Andrés M., Banwell, Brenda, Marignier, Romain, Pittock, Sean J., Greenberg, Benjamin , Bennett, Jeffrey L., Cho, Tracey, Clardy, Stacey, Solomon, Andrew J., Ja, Gelfand, Obeidat, Ahmed Z., Blackburn, Kyle, Tenembaum, Silvia , Chen, John J., Sotirchos, Elias S., Levy, Michael, Flanagan, Eoin P., Group, and The Americas MOGAD Treatment, Murillo, Fabian, Syc-Mazurzek, Stephanie B., Jiang, Mulan , Rezende, N, Wingerchuk, D M, Horsman, Susan E. , Bilodeau, Philippe‐Antoine , Bilodeau, Philippe A , Vilaseca, Andreu , Hooshmand, Sam , Moseley, Carson E. , Marrodán, Mariano , Vanegas, Adriana Casallas , Hoshina, Yoji , Contentti, Edgar Carnero , Galleguillos, Lorna , Virupakshaiah, Akash , Arrambide, Georgina , Caparó‐Zamalloa, César , Waubant, Emmanuelle L. , Ordóñez-Boschetti, Laura, Villa, Andres Maria , Marignier, Romain , Pittock, Sean J. , Bennett, Jeffrey L. , Cho, Tracey , Clardy, Stacey , Solomon, Andrew , Kister, Ilya , Zamvil, Scott S. , Gelfand, Jeffrey M. , Repovic, Pavle , Obeidat, Ahmed Zayed , Blackburn, Kyle , Chen, John J., Sotirchos, Elias S. , Levy, Michael , Flanagan, Eoin P. , Syc‐Mazurek, Stephanie B. , Cacciaguerra, Laura , Rezende, Nathane Braga da Silva, Wingerchuk, Dean M.

Mayo Clinic

JAMA Neurology | July 13, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamaneurol.2026.2220 | PMID 42440328 Get It

Importance Myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) lacks proven relapse-preventive therapies. While clinical trials are ongoing, safety data may be limited and approved drugs are costly. Studies of interleukin 6 receptor blocker (IL-6RB) in MOGAD are limited by small numbers and no comparative studies, contributing to low use. Objective To evaluate the impact of IL-6RB therapy on relapse rates in MOGAD and compare relapse frequency with intravenous immunoglobulin (IVIG). Design, Setting, and Participants This international, multicenter, retrospective cohort study (January 1, 2015, through December 31, 2025) included a historical IVIG-treated cohort of varying doses. The study took place across sites in North and South America (US, Canada, Mexico, Argentina, Brazil, Chile, Colombia, and Peru). Patients with MOGAD (n = 116, no excluded patients) who received at least 1 dose of an IL-6RB were included. These data were analyzed in January 2026. Exposures Tocilizumab or satralizumab. Main Outcomes and Measures Annualized relapse rate (ARR) during IL-6RB therapy, time to next relapse after treatment initiation, and adverse events. Outcomes were compared with the IVIG cohort using inverse probability of treatment weighting (IPTW) adjusted for age, sex, prior ARR, and concomitant therapies. Results A total of 116 patients with MOGAD (89% relapsing) receiving IL-6RB (tocilizumab, 104 [90%] and satralizumab, 12 [10%]) were included; overall, 60.3% were female, 39.7% were male, and 18% were younger than 18 years. The median (IQR) IL-6RB treatment follow-up was 1.4 (0.7-2.5) years and 23 relapses occurred during 241.8 person-years of IL-6RB therapy. The ARR decreased from 0.64 (95% CI, 0.58-0.70) for relapsing MOGAD before IL-6RB to 0.09 (95% CI, 0.06-0.14) during IL-6RB treatment (incidence rate ratio, 0.08; 95% CI, 0.04-0.16). Adverse events occurred in 58 patients (50%), most commonly mild infections, although 10 (9%) had severe infections. In the IVIG cohort (n = 59), 30 relapses occurred over 133.8 person-years (ARR, 0.22; 95% CI, 0.15-0.32). After IPTW, IL-6RB was associated with a lower hazard ratio (HR) than the group who underwent IVIG therapy less than 1 g/kg every 4 weeks (HR, 4.5; 95% CI, 2.0-9.8), with no significant difference vs the group who underwent IVIG 1 g/kg or more every 4 weeks (HR, 2.0; 95% CI, 0.8-4.5). Conclusions and Relevance In this multicenter observational cohort, IL-6RB use in MOGAD was associated with low relapse rates and a favorable safety profile, though severe infections occurred occasionally. Relapse rates were lower than the group who underwent IVIG less than 1 g/kg every 4 weeks but not significantly different from the group who underwent IVIG 1 g/kg or more every 4 weeks. This supports IL-6RB as a potential relapse-prevention therapy in MOGAD; the wide availability and relative affordability of tocilizumab may enable broad global use.
Adenotonsillectomy is associated with increased risk and disease activity in pediatric-onset multiple sclerosis
Chang, Gina , Nasr, Z., Schoeps, Vinícius Andreoli , Virupakshaiah, Akash , Zamvil, Scott S, Moseley, Carson E. , Chong, Janet, Graves, Jennifer , Waltz, Michael , Tillema, Jan-Mendelt, Abrams, Aaron , Mar, Soe, Schreiner, Teri , Rose, John W. , Casper, T Charles, Nasr, Zahra , Graves, Jennifer , Rodriguez, Moses , Chitnis, Tanuja , Rensel, Mary R. , Abrams, Aaron , Krupp, Lauren , Schreiner, Teri , Rose, John W , Waubant, Emmanuelle L. , Virupakshaiah, Akash , Zamvil, Scott S. , Sabatino, Joseph J. , Chong, Janet, Rodriguez, Moses , Tillema, Jan‐Mendelt , Krupp, Lauren , Waldman, Amy , Mar, Soe , Casper, T. Charles

Mayo Clinic

Multiple Sclerosis Journal | May 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/13524585261444244 | PMID 42212792 Get It

Background: Epstein–Barr virus (EBV) is a key environmental risk factor for multiple sclerosis (MS), and tonsils and adenoids serve as a primary viral reservoir. This study investigates the potential role of adenotonsillectomy in pediatric-onset multiple sclerosis (POMS) risk and relapse rate. Objectives: POMS participants and controls were recruited from 16 pediatric MS clinics between 1 November 2011 and 1 July 2017. Clinical and demographic information, including history of adenotonsillectomy, EBV serostatus, and HLA-DRB1*15:01:01 status, were collected. Multivariable logistic regression assessed the association between adenotonsillectomy and MS risk. In addition, negative binomial regression offset by follow-up time was used to assess the relationship between adenotonsillectomy and relapse rate in POMS participants with available follow-up data. Results: The case-control analysis included 359 POMS participants and 560 pediatric controls. Individuals with a history of adenotonsillectomy had a 63% increased odds of MS (adjusted odds ratio (OR) = 1.63, 95% confidence interval (CI) = 1.01–2.64, p = 0.046). Among the 239 POMS participants with available follow-up data, adenotonsillectomy was associated with a twofold increase in annualized relapse rate (adjusted incidence rate ratio (IRR) = 2.00, 95% CI = 1.15–3.48, p = 0.013). Conclusions: Prior adenotonsillectomy was associated with increased risk of MS and greater relapse rate in pediatric patients, suggesting a potential interplay between EBV, immune regulation, and MS pathogenesis.
Staffing, accepted indications, and dose of Phase II cardiac rehabilitation: country income class and time-based comparisons from the International Council of Cardiovascular Prevention and Rehabilitation’s (ICCPR) 2025 Audit Update
Mampuya, Warner , Jiandani, Mariya P , Mbau, Lilian, Rivero, Monserrat Cruz , Anchique, Claudia V. , 丁荣晶 , Schalkwijk, Dinah L. van , Gallagher, Jonathan , Fernández, Rosalia, Maskhulia, L , Martinez, Jimena, Botha, Noel V Hau, Champaiboon, Jirapa , Yokoyama, Miho, Investigators, ICCPR Global Cardiac Rehabilitation Audit Update, Akinci, Buket, Carson, Rachael Pamela, Quesada-Chaves, Daniel F, Norekvål, Tone M, Kouidi, Evangelia , Таргыновна, Аймакова Гульсим, Quito, Benjamin Jose, Lima de Melo Ghisi, Gabriela , Turk-Adawi, Karam , Mampuya, Warner M , Jiandani, Mariya P , Mbau, Lilian , Cruz Rivero, Monserrat , Anchique, Claudia V , Gallagher, Jonathan , Gaye, Ngone Diaba , Kim, Won-Seok , Seron, Pamela , Maskhulia, Lela , Batalik, Ladislav , Chen, Ssu-Yuan , Supervía, Marta , Champaiboon, Jirapa , Grace, Sherry L , Mettananda, Chamila Dinushi Kukulege , Baťalík, Ladislav , Yokoyama, Miho Nishitani , Grace, Sherry L. , Akıncı, Buket , Candelaria, Dion , Quesada-Chaves, Daniel, Norekvål, Tone M. , Szadkowska, Iwona , Jug, Borut , Aimakova, Gulsim T., Radi, Basuni

Mayo Clinic

European Journal of Preventive Cardiology | May 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurjpc/zwag292 | PMID 42207983 Get It

Abstract Aims To characterize global variation in cardiac rehabilitation (CR) staffing, indications, and prescribed dose by country income classification and compare findings with the International Council of Cardiovascular Prevention and Rehabilitation’s 2016 Global Audit. Methods and results Cross-sectional REDCap survey of Phase II/post-discharge CR programmes (May–September 2025). Outcomes were multidisciplinary team size/composition, accepted cardiac and non-cardiac indications, and centre-based CR dose. Comparisons were made across World Bank country income classifications and Audit decade (2016 vs. 2025). Of 7025 programmes identified globally, 1505 (median programme response rate = 62%/country) initiated a survey, from 90/113 (80%) countries with CR. CR was delivered by a multidisciplinary team of 7 (median; P25–P75 = 5–8; nurses, physiotherapists, cardiologists, and dietitians most common); teams were smaller in low-income countries (median = 4; P < 0.001), and physician specialty varied. Non-low-income programmes consistently accepted (≥90%) patients with acute coronary syndrome, with programmes in low-income countries less often accepting related interventions (e.g. surgery: low-income 0% vs. high-income 97%; P < 0.01), but non-cardiac indications were more frequently accepted (e.g. primary prevention, diabetes, and lung disease). Acceptance of heart failure increased compared with the previous Audit (70% vs. 87%; P < 0.001). Centre-based programmes prescribed a median of 20 h (P25–P75 = 12–30), typically two sessions/week over 8 weeks. Globally, 65 (72%) countries prescribed a median ≥12 sessions/programme. Programmes in upper-middle-income countries prescribed more sessions (median = 24, P25–P75 = 12–36; P < 0.001). Dose did not differ meaningfully between Audits (P = 0.07). Conclusion CR programmes globally are offered by small, but multidisciplinary teams. They accept guideline-indicated patients, with applicable variation by context. Insufficient dose in one-quarter of countries underscores investment need.
Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE
Bahlis, Nizar J. , Facon, Thierry, San-Miguel, Jesus, Usmani, Saad Z., Dimopoulos, Meletios-Athanasios A., Moreau, Philippe, Manier, Salomon , NS, Raje, Orlowski, Robert Z. , Goldschmidt, H, Hulin, Cyrille, Weisel, K, Leleu, Xavier, Plesner, Torben , Jakubowiak, Andrzej J, Cook, Gordon, Quach, H, Venner, Christopher P., Cavo, M, Ngo, Mai, Bolyard, Kasey, Carson, R, Borgsten, Fredrik, Mateos, María‐Victoria , Kumar, Shaji , Miguel, Jesús F. San , Bahlis, Nizar Jacques , San-Miguel, Jesus , Zweegman, Sonja , Perrot, Aurore , Manier, Salomon , Orlowski, Robert Z. , Goldschmidt, Hartmut , Mohty, Mohamad , Leleu, Xavier , Cook, Gordon , Quach, Hang , Mateos, María-Victoria , Kumar, Shaji K , Facon, Thierry T.F. , Usmani, Saad Z. , Dimopoulos, Meletios A , Moreau, Philippe , Chari, Ajai , Goldschmidt, Hartmut , Basu, Supratik , Hulin, Cyrille , Weisel, Katja C , Mohty, Mohamad , Leleu, Xavier , Jakubowiak, Andrzej , Cook, Gordon , Quach, Hang , Cavo, M., Carson, Robin

Mayo Clinic

Blood Advances | May 5, 2026 | Volume: 10 | Issue: 13 | Pages: 4541-4550

10.1182/bloodadvances.2025019323 | PMID 42085642 Get It

Abstract Both the phase 3 MAIA and ALCYONE studies demonstrated significant survival benefit with the addition of daratumumab to standard-of-care Rd (Revlimid [lenalidomide] and dexamethasone; D-Rd) or to VMP (Velcade [bortezomib], melphalan, and prednisone; D-VMP), respectively, vs Rd or VMP alone in transplant-ineligible newly diagnosed multiple myeloma (NDMM). Patients with NDMM are highly susceptible to infection; therefore, gaining a greater understanding of infection incidence may help to mitigate future risk. We conducted a pooled analysis of infection incidence, timing, and management strategies from MAIA and ALCYONE. The median (range) age of the pooled population was 72 (40-93) years. Incidence was higher with D-Rd/D-VMP vs Rd/VMP for grade 3/4 (36.9% vs 22.4%) and grade 5 (3.0% vs 1.5%) infections; however, exposure-adjusted incidence rates were generally comparable between groups. Any-grade infections led to the discontinuation of study treatment in ∼2% of patients across treatment groups. Of the timing intervals explored, the highest incidence of grade 3/4 infection occurred within the first 6-month interval of study treatment initiation in both groups. Median time to the first onset of grade 3/4 infections (per Kaplan-Meier estimates) was 83.3 months and not estimable in the D-Rd/D-VMP and Rd/VMP groups, respectively. Although the rates of D-Rd/D-VMP treatment discontinuation due to infection remained low in MAIA and ALCYONE, clinicians should remain vigilant about infections throughout treatment and follow local guidelines and International Myeloma Working Group recommendations to minimize the risk of infection. These trials were registered at www.ClinicalTrials.gov as NCT02252172 (MAIA) and NCT02195479 (ALCYONE).
Association of patient complexity with information processing and usability of electronic health records among ICU providers: a multicenter study
Khairat, Saif , Morelli, Joseph G. , Yang, Shiyi , Li, Yining, Mohan, Deepika , Ratwani, Raj M, Apathy, Nate C., Boynton, Marcella H, Carson, Shannon S, Khairat, Saif , Morelli, Jennifer , Herasevich, Vitaly , Apathy, Nate C , Herasevich, Vitaly , Handzel, Robert M. , Ratwani, Raj M. , Boynton, Marcella H. , Carson, Shannon S.

Mayo Clinic

Journal of the American Medical Informatics Association | January 21, 2026 | Volume: 33 | Issue: 4 | Pages: 881-889

10.1093/jamia/ocag017 | PMID 41719162 Get It

Abstract Objective This study aimed to evaluate how differences in case complexity affect information-processing burden, as measured by eye-tracking, as well as the efficiency of electronic health record (EHR) use among healthcare providers in the intensive care unit. Materials and Methods This cross-sectional study recruited providers from 4 U.S. medical centers that use 2 prominent EHR systems (Epic and Oracle). After reporting demographic information, participants reviewed 2 complex cases and 2 standard cases in their institution’s EHR system and then responded to 5 questions about each case, yielding a performance score. Information-processing burden was assessed by measuring the number of eye fixations via eye-tracking software. The efficiency of EHR use was assessed by measuring the task completion time, number of mouse clicks per minute, number of EHR screens viewed, and performance score. Results Eighty-one providers were included for analysis. Providers exhibited significantly more eye fixations (P < .001) and longer task completion times (P < .001) for complex cases than for standard cases. There were also significantly fewer mouse clicks per minute during complex cases (P < .001). Reviewing a complex case first led to significantly more eye fixations (P = .015) and longer task completion times (P < .01) than when a standard case was presented first. Case complexity did not significantly affect performance scores or the number of EHR screens viewed. Discussion Higher case complexity was shown to be associated with greater information-processing burden and less efficient EHR use. These findings have implications for enhancing the efficiency of EHR use, thereby leading to improved clinical decision-making and patient safety. Furthermore, reviewing complex cases first led to a greater information-processing burden, suggesting that providers could benefit from “warming up” with standard cases before reviewing complex cases.